Clinical Trial Update: Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for IMM0306 in relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd20-positive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• IMM0306

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: CD20-positive B-cell Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN